Update Provided Phase I Study of MT-5111 in HER2-positive Cancers
Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time
AUSTIN, Texas, June 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates, MTEM or the Company), a clinical-stage biopharmaceutical company focused on the discovery and development of the Companys proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), announced that four poster presentations featuring pre-clinical data on its pipeline programs are being presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, being held June 22-24, 2020. Copies of the posters presented at AACR can be found in the Presentations section of Molecular Templates website at http://ir.mtem.com/events-and-presentations/presentations. MTEM also announced an update on its ongoing Phase I study of MT-5111 in HER2-positive cancers.
Poster Title: In Vivo Efficacy of a PD-L1 Targeted, Antigen Seeding Engineered Toxin Body
MT-6402 is a unique agent designed to deplete tumor and repressive immune cells in the tumor microenvironment. It has multiple unique mechanisms of action that may provide greater potency than is seen with current PD-L1 antibodies. MT-6402 was shown to have potent in vitro activity against a variety of PD-L1+ tumor cells and results in tumor growth delay and survival benefits in NSCLC PDX in vivo model. MT-6402 can alter the immunophenotype of the tumor and allow for recognition by effector T cells. Non-human primate (NHP) data show that MT-6402 mediated PD-L1+ immune cell clearance can elicit highly potent monotherapy immune activation in a way that has not been seen previously in NHP models with checkpoint inhibitors. MT-6402 is slated for IND filing in 2H20.
Poster Title: CTLA-4 Targeted Engineered Toxin Bodies Designed to Deplete Regulatory T Cells (Tregs)
Tumor resident regulatory T cells (Tregs) are important mediators of an immunosuppressive tumor microenvironment (TME) promoting tumor immune evasion. The presence of Tregs, and a higher ratio of Tregs to effector T cells in the TME, are associated with poor prognosis. There is concern that antibodies to CTLA-4 are not sufficiently effective at clearing Tregs from the TME. ETBs are being developed to specifically target CTLA-4+ Tregs and clear them from the TME. Because CTLA-4-targeted ETBs preferentially affect Tregs versus CTLA-4+ CD8 T-cells, ETBs may also have a safer profile than CTLA-4 antibodies. In co-culture models CTLA-4 ETBs were shown to relieve Treg suppression of T-effector proliferation. Experiments in mice showed that CTLA-4 ETB 1 (as labeled on the AACR poster) displays a short serum half-life and is well tolerated in vivo. An IND for a CTLA-4 ETB is expected to be filed in 2021.
Poster Title: Novel Engineered Toxin Bodies Targeting SLAMF7 (CS1)
SLAMF7 (CS1) is a clinically validated target of monoclonal antibody therapy for the treatment of multiple myeloma. The approved antibody-based therapeutic, elotuzumab, works indirectly by recruiting effector cells to the tumor but does not show single agent clinical activity. ETBs have the potential to deplete malignant cells by means of potent and direct cell kill through enzymatic ribosomal destruction. SLAMF7 ETBs were shown to be active alone and in the presence of elotuzumab. Epitopes distinct from elotuzumab are options for ETB engagement, allowing activity in the presence of elotuzumab. SLAMF7 ETBs combine with standard of care chemotherapy (IMiDs) and bortezomib in a positive manner in vitro. Lead selection is underway with the testing of various ETB scaffolds and additional binding domains targeting multiple SLAMF7 epitopes.
Poster Title: CD45 Targeted Engineered Toxin Bodies Deplete Hematopoietic and Malignant Cells
CD45, the leucocyte common antigen, is a haemopoietic cell-specific tyrosine phosphatase. Targeted and potent ETBs with intrinsically short half-lives are being developed to specifically destroy CD45 expressing cells including malignant cells of B, T and myeloid lineage. A single agent, targeted conditioning method for bone marrow transplant (BMT), employing ETBs, has the potential to increase patient safety and eliminate genotoxic effects that are associated with existing conditioning regimens. Antibody discovery campaigns have the potential to direct ETBs to specific isoforms of CD45 for refinement of indications including various cancers and autoimmune diseases.
Update on Phase I study of MT-5111
MT-5111, a HER2 targeted ETB, is in an ongoing Phase 1 study that has two parts: Part 1 is dose escalation and Part 2 is dose expansion, which will begin when a maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) is established in Part 1. To date, 10 subjects, with a median of 5 prior lines of therapy and a median of 2 prior HER2-targeting regimens, have been treated with MT-5111 (metastatic cholangiocarcinoma n=5, metastatic breast cancer n=4, metastatic gastro-esophageal junction carcinoma n=1). Thus far, no dose limiting toxicities (DLTs) have been observed in any cohort and MT-5111 appears to be well tolerated, with no cardiotoxicity to date (cardiotoxicity is a known potential toxicity for HER2 targeted therapies).
Currently there are 4 subjects in total on treatment from the second (1 g/kg/dose) and third cohorts (2 g/kg/dose). No cardiac AEs or abnormalities in cardiac biomarkers have been noted thus far. Reported AEs that may be causally related among the 3 cohorts to date include the following: one instance of grade 1 chills, one instance of grade 1 hypophosphatemia, one instance of grade 1 nausea, and one instance of grade 2 AST elevation. The grade 2 AST elevation occurred in a subject in cohort 1 with disease progression in hepatic metastases; no causally related AST or ALT elevations have been noted in any other subjects to date. The ongoing subject from cohort 2 (45 y/o female with metastatic breast cancer) has stable disease (the subject only has evaluable disease but no measurable lesions per RECIST 1.1, and is classified as non-CR, non-PD per protocol) and remains on treatment, now in cycle 5. One subject in cohort 3 with metastatic breast cancer has had a follow-up CT scan at the end of cycle 2 and has stable disease. Six subjects have discontinued for disease progression and two subjects are too early to evaluate. Cohort 4 (3.0 g/kg/dose) is anticipated to open shortly. Molecular Templates is encouraged by the safety profile to date in these heavily pretreated patients and expects to provide an update on results from the patients currently on treatment as well as higher dose cohorts from the dose escalation portion of the Phase 1 study (including doses that are predicted to be clinically active based on preclinical data) in 4Q20.
Conference Call and Webcast to Discuss AACR Posters
Molecular Templates will host a live webcast and conference call in Eric Poma, Ph.D., Molecular Templates Chief Executive Officer and Scientific Officer, will provide an update on the Companys pipeline programs and discuss the four abstracts presented at AACR.
Thursday, June 25th at 10:30am Eastern Time
Domestic: 877-705-6003International: 201-493-6725Conference ID: 13704222Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1322770&tp_key=655ccca2f4
The Molecular Templates management team will be available for a question and answer session at the conclusion of this call.
About Molecular Templates Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.
Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Molecular Templates disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Acts Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words may, could, should, anticipate, believe, estimate, expect, intend, plan, predict and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the Companys options with respect to the second and third tranche term loans.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether the Company will achieve its expected milestones; risks from global pandemics including COVID-19; whether the Companys cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; the ability of the Company to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading Risk Factors in the Companys filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise
Investor Contact:Adam CutlerChief Financial Officeradam.cutler@mtem.com862-204-4006
Source: Molecular Templates, Inc.
Go here to read the rest:
- History of Evolution | Internet Encyclopedia of Philosophy - December 9th, 2016 [December 9th, 2016]
- Evolution - Bulbapedia, the community-driven Pokmon encyclopedia - December 12th, 2016 [December 12th, 2016]
- What is Evolution - explanation and definitions - December 21st, 2016 [December 21st, 2016]
- Evolution (2001 film) - Wikipedia - January 28th, 2017 [January 28th, 2017]
- EvolutionM.net - Mitsubishi Lancer Evolution | Reviews, News ... - February 1st, 2017 [February 1st, 2017]
- YMCA evolution continues at lake - Gaston Gazette - February 7th, 2017 [February 7th, 2017]
- Ivanka Trump's Beauty Evolution, From 1998 to Today Watch - Us Weekly - February 7th, 2017 [February 7th, 2017]
- Lumpy, hairy, toe-like fossil could reveal the evolution of molluscs - The Guardian - February 7th, 2017 [February 7th, 2017]
- How Evolution Alters Biological Invasions - ScienceBlog.com (blog) - February 7th, 2017 [February 7th, 2017]
- Cultural evolution and the mutilation of women - The Economist - February 7th, 2017 [February 7th, 2017]
- Late-night hosts on the evolution of Trump: 'Dickish to dictatorish' - The Guardian - February 7th, 2017 [February 7th, 2017]
- Gold's Gym Regina rebrands to become Evolution Fitness - Regina Leader-Post - February 7th, 2017 [February 7th, 2017]
- Incremental Versus Radical Innovation: A Response to Josh Swamidass on Evolution and Cancer - Discovery Institute - February 7th, 2017 [February 7th, 2017]
- Blockchain: Investment (R)Evolution For Developing Markets - Forbes - February 7th, 2017 [February 7th, 2017]
- See the Evolution of the Famed Porsche 911 in 7 Photos - WIRED - February 7th, 2017 [February 7th, 2017]
- Exhibition charts 500 years of evolution of robots - Phys.Org - February 7th, 2017 [February 7th, 2017]
- How evolution turned ordinary plants into ravenous meat-eaters - Wired.co.uk - February 7th, 2017 [February 7th, 2017]
- Are Evolution Fresh Drinks 'Poison'? - snopes.com - February 7th, 2017 [February 7th, 2017]
- Non-Chromosomal DNA Drives Tumor Evolution - The Scientist - February 8th, 2017 [February 8th, 2017]
- Chimpanzee feet allow scientists a new grasp on human foot evolution - Phys.Org - February 8th, 2017 [February 8th, 2017]
- 'Goldilocks' genes that tell the tale of human evolution hold clues to variety of diseases - Science Daily - February 8th, 2017 [February 8th, 2017]
- Pac-Man is Coming to 'The Sandbox Evolution' Next Week - Touch Arcade - February 9th, 2017 [February 9th, 2017]
- Chimpanzee feet allow scientists a new grasp on human foot ... - Science Daily - February 9th, 2017 [February 9th, 2017]
- Bacteria sleep, then rapidly evolve, to survive antibiotic treatments - Phys.Org - February 9th, 2017 [February 9th, 2017]
- Orangutan squeaks reveal language evolution, says study - BBC ... - BBC News - February 9th, 2017 [February 9th, 2017]
- Evolution gives rhyme its reason - Aurora News Register - February 9th, 2017 [February 9th, 2017]
- Deeper origin of gill evolution suggests 'active lifestyle' link in early vertebrates - Science Daily - February 9th, 2017 [February 9th, 2017]
- From Tara Palmer-Tomkinson to Cara Delevingne: the evolution of the It girl - The Guardian - February 10th, 2017 [February 10th, 2017]
- Banned TED Talk: Rupert Sheldrake The Science Delusion - Collective Evolution - February 10th, 2017 [February 10th, 2017]
- VOTD: Watch the Evolution of Keanu Reeves' Acting Career - /FILM - February 10th, 2017 [February 10th, 2017]
- Pokmon Go Eevee evolution: How to evolve Eevee into Vaporeon, Jolteon and Flareon with new names - Eurogamer.net - February 10th, 2017 [February 10th, 2017]
- Horse evolution bucks evolutionary theory - Science News - February 10th, 2017 [February 10th, 2017]
- Samsung's Chromebook Pro highlights the category's continued evolution - TechCrunch - February 10th, 2017 [February 10th, 2017]
- Scientists solve fish evolution mystery - Phys.Org - February 10th, 2017 [February 10th, 2017]
- Wildfire evolution forces Forest Service into new thinking - The Daily Progress - February 11th, 2017 [February 11th, 2017]
- How the horse can help us answer one of evolution's biggest questions - Raw Story - February 11th, 2017 [February 11th, 2017]
- A primer on Darwin Day: Some religious groups embrace 'Theistic evolution' - LancasterOnline - February 11th, 2017 [February 11th, 2017]
- Apple: Evolution of in-car audio tech moving at 'speed of sound ... - Times of India - February 11th, 2017 [February 11th, 2017]
- Mariska Hargitay's Evolution from '80s Glam to Law & Order: Special Victims Unit - TVOvermind - February 12th, 2017 [February 12th, 2017]
- Evolution of baseball from power to speed has left SBs behind ... - Chicago Sun-Times - February 12th, 2017 [February 12th, 2017]
- More order with less judgment: An optimal theory of the evolution of cooperation - Science Daily - February 12th, 2017 [February 12th, 2017]
- J. Albert C. Uy speaks on evolution, biodiversity in bellied flycatcher population - The College Reporter - February 12th, 2017 [February 12th, 2017]
- See the Evolution of Movie Magic With Every Oscar Winner for Visual Effects in History - Gizmodo - February 12th, 2017 [February 12th, 2017]
- Numerology: Here's What Your Name Says About You - Collective Evolution - February 13th, 2017 [February 13th, 2017]
- The Evolution of Valentine's Day - Inside Science News Service - February 13th, 2017 [February 13th, 2017]
- Why evolution may be tech billionaires' biggest enemy - The Week Magazine - February 13th, 2017 [February 13th, 2017]
- Community Viewpoint: Evolution, like gravity, is much more than theory it is a fact - Kdminer - February 13th, 2017 [February 13th, 2017]
- How the horse can help us answer one of evolution's biggest questions - Phys.Org - February 13th, 2017 [February 13th, 2017]
- How evolution alters biological invasions - Science Daily - February 13th, 2017 [February 13th, 2017]
- Cockeyed squid shines light on deep sea evolution - Christian Science Monitor - February 13th, 2017 [February 13th, 2017]
- Eye Evolution: A Closer Look - Discovery Institute - February 14th, 2017 [February 14th, 2017]
- Evolution always wins: University of Idaho video game uses mutating aliens to teach science concepts - The Spokesman-Review - February 14th, 2017 [February 14th, 2017]
- Geneticists track the evolution of parenting - Phys.Org - February 14th, 2017 [February 14th, 2017]
- How this cockeyed squid shines a light on deep sea evolution - Christian Science Monitor - February 14th, 2017 [February 14th, 2017]
- 4 Possible Roadmaps For macOS and iOS Evolution - The Mac Observer (blog) - February 15th, 2017 [February 15th, 2017]
- The Evolution of the Energy Capital of the World - Texas Monthly - February 15th, 2017 [February 15th, 2017]
- Humons presents an atypical dance evolution - Detroit Metro Times - February 15th, 2017 [February 15th, 2017]
- Pokemon Go Adds 80 Generation 2 Pokemon, New Evolution Items This Week - IGN - February 15th, 2017 [February 15th, 2017]
- Fossil discovery rewrites understanding of reproductive evolution ... - Science Daily - February 15th, 2017 [February 15th, 2017]
- 'X-Men: Evolution' Is the Gateway Drug of Comic Book Shows - Geek - February 16th, 2017 [February 16th, 2017]
- A cultural catch: Evolution of wooden halibut hooks carved by native ... - Science Daily - February 16th, 2017 [February 16th, 2017]
- Bremerton's Fitness Evolution now Planet Fitness - Kitsap Sun (blog) - February 16th, 2017 [February 16th, 2017]
- Eye Evolution: The Waiting Is the Hardest Part - Discovery Institute - February 16th, 2017 [February 16th, 2017]
- Evolution Of The Yeezy: 2009-2017 - HotNewHipHop - February 16th, 2017 [February 16th, 2017]
- Prebiotic evolution: Hairpins help each other out - Science Daily - February 16th, 2017 [February 16th, 2017]
- This 'Live Birth' Fossil Could Change Humanity's Understanding Of Evolution - Daily Caller - February 16th, 2017 [February 16th, 2017]
- Mysterious Ancient Stonehenge-Like Circles Found in Amazon Rainforest - Collective Evolution - February 16th, 2017 [February 16th, 2017]
- 'Pokemon Go': How to Evolve Poliwhirl Into Politoed - Heavy.com - February 17th, 2017 [February 17th, 2017]
- 'Pokemon Go': How to Evolve Slowpoke Into Slowbro or Slowking - Heavy.com - February 17th, 2017 [February 17th, 2017]
- 'Pokemon Go': How to Evolve Gloom Into Bellossom - Heavy.com - February 17th, 2017 [February 17th, 2017]
- Pokmon Go Dragon Scale - how to evolve Seadra into Kingdra and how to get the Dragon Scale - Eurogamer.net - February 17th, 2017 [February 17th, 2017]
- Pokmon Go Eevee evolution: How to evolve Eevee into Umbreon, Espeon, Vaporeon, Jolteon and Flareon with new ... - Eurogamer.net - February 17th, 2017 [February 17th, 2017]
- University of Pittsburgh guest speaker discloses evolution findings - UTA The Shorthorn - February 17th, 2017 [February 17th, 2017]
- 'Pokemon Go' Special Items: Drop Rates for Evolution Items & Berries at Pokestops - Heavy.com - February 17th, 2017 [February 17th, 2017]
- How Vedic Philosophy Influenced Nikola Tesla's Idea of 'Free Energy' - Collective Evolution - February 18th, 2017 [February 18th, 2017]
- Migration to America took long enough for evolution to happen on the way - Ars Technica - February 18th, 2017 [February 18th, 2017]
- How To Choose Your Eevee Evolution In 'Pokmon GO:' Umbreon And Espeon Edition - Forbes - February 18th, 2017 [February 18th, 2017]
- Evolution Items - IGN - February 18th, 2017 [February 18th, 2017]
- Congo River fish evolution shaped by intense rapids: Genomic study ... - Science Daily - February 18th, 2017 [February 18th, 2017]
- Pokmon Go - How to evolve, use Special Items, when to evolve or Power Up your Pokmon - Eurogamer.net - February 18th, 2017 [February 18th, 2017]